Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Al's Fun who wrote (149)	8/19/1999 7:51:00 AM
From: Jim Oravetz	Read Replies (1) of 370

Your right. Not much interest. This company recently released the Q report. Nothing out of the ordinary for a start-up biotech -- continuing spending more than income. Nice to see some uptick in earnings. Long term speculative buy. This is a local issue for me(new haven,ct), so I've been interested in tracking their progress. Ties with Yale means that they have some good researchers and science on the job. The BOD also has lots of drug/biotech experience. Not sure about the CEO however. He ran another local company (rumor has it, not too well), retired, then popped up first on the BOD, now in the top spot. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next